Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma

Virchows Archiv

Volumn 463, Issue 5, 2013, Pages 623-631

  Rössle, Matthias ^a   Sigg, Michèle ^a   Rüschoff, Jan H ^a   Wild, Peter J ^a   Moch, Holger ^a   Weber, Achim ^a   Rechsteiner, Markus P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

BRAF mutation; Colorectal carcinoma; Immunohistochemistry; Sanger sequencing; Ultra deep sequencing

Indexed keywords

B RAF KINASE; MONOCLONAL ANTIBODY;

ADULT; AGED; AMPLICON; ANALYZER; ARTICLE; BRAF GENE; CANCER CELL; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; ULTRA DEEP SEQUENCING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84888994058     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1492-3     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians 61(2):69-90. doi: 10.3322/caac.20107
2. Ries L, Young J, Keel G, Eisner M, Lin Y, Horner M-J (2007) SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, Bethesda, MD
3. Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011-2019. doi: 10.1200/JCO.2010.33.5091
4. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705-5712. doi: 10.1200/JCO.2008.18.0786
5. Bokemeyer C, Cutsem EV, Rougier P et al (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466-1475. doi: 10.1016/j.ejca.2012.02.057
6. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE 7(10):e47054. doi: 10.1371/journal.pone.0047054
7. Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in Stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Journal of Clinical Oncology 28(3):466-474. doi: 10.1200/jco.2009.23.3452
8. Fransén K, Klintenäs M, Österström A, Dimberg J, Monstein H-J, Söderkvist P (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25(4):527-533. doi: 10.1093/carcin/bgh049
9. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954. doi: 10.1038/nature00766
10. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418(6901):934-934. doi: 10.1038/418934a
11. Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV (2012) Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer. J Natl Cancer Inst 104(23):1785-1795. doi: 10.1093/jnci/djs433
12. Blank PR, Moch H, Szucs TD, Schwenkglenks M (2011) KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clinical Cancer Research 17(19):6338-6346. doi: 10.1158/1078-0432.CCR-10-2267
13. Lamy A, Blanchard F, Le Pessot F et al (2011) Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 24(8):1090-1100. doi: 10.1038/modpathol.2011.60
14. Anderson S, Bloom KJ, Vallera DU et al (2012) Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Archives of Pathology & Laboratory Medicine 136(11):1385-1391. doi: 10.5858/arpa.2011-0505-OA
15. Rechsteiner M, von Teichman A, Rüschoff JH et al (2013) KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. The Journal of Molecular Diagnostics 15(3):299-311. doi: 10.1016/j.jmoldx.2013.02. 001
16. Raab SS (2000) The cost-effectiveness of immunohistochemistry. Archives of Pathology & Laboratory Medicine 124(8):1185-1191. doi: 10.1043/0003-9985(2000)124<1185:tceoi>2.0.co;2
17. Capper D, Preusser M, Habel A et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122(1):11-19. doi: 10.1007/s00401-011-0841-z
18. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. The American Journal of Surgical Pathology 36(12):1796-1800. doi: 10.1097/PAS.0b013e3182549b50
19. Bösmüller H, Fischer A, Pham DL et al (2013) Detection of the BRAFV600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Human Pathology 44(3):329-335. doi: 10.1016/j.humpath.2012. 07.010
20. V600E detection in papillary thyroid carcinoma. Endocrine-Related Cancer 19(6):779-784. doi: 10.1530/erc-12-0239
21. Capper D, Berghoff A, Magerle M et al (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123(2):223-233. doi: 10.1007/s00401-011-0887-y
22. Ilie M, Long E, Hofman V et al (2012) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Annals of Oncology 24(3):742-748. doi: 10.1093/annonc/mds534
23. Koperek O, Kornauth C, Capper D et al (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. The American Journal of Surgical Pathology 36(6):844-850. doi: 10.1097/PAS. 0b013e318246b527
24. Long GV, Wilmott JS, Capper D et al (2013) Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. The American Journal of Surgical Pathology 37(1):61-65. doi: 10.1097/PAS.0b013e31826485c0
25. Preusser M, Capper D, Berghoff AS et al (2013) Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Applied immunohistochemistry & molecular morphology 21(2):159-164
26. Sahm F, Capper D, Preusser M et al (2012) BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 120(12):e28-e34. doi: 10.1182/blood-2012-06-429597
27. Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844-847. doi: 10.1038/nm0798-844
28. Colomba E, Hélias-Rodzewicz Z, Von Deimling A et al (2013) Detection of BRAF p.V600E Mutations in Melanomas: Comparison of Four Methods Argues for Sequential Use of Immunohistochemistry and Pyrosequencing. The Journal of Molecular Diagnostics 15(1):94-100. doi: 10.1016/j.jmoldx.2012.09.001
29. Affolter K, Samowitz W, Tripp S, Bronner MP (2013) BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes, Chromosomes and Cancer 52(8):748-752. doi: 10.1002/gcc.22070
30. Adackapara CA, Sholl LM, Barletta JA, Hornick JL (2013) Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 63(2):187-193. doi: 10.1111/his.12154
31. De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 11(8):753-762. doi: 10.1016/S1470-2045(10)70130-3
32. Capper D, Voigt A, Bozukova G et al (2013) BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 133(7):1624-1630. doi: 10.1002/ijc.28183
33. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clinical Cancer Research 16(3):790-799. doi: 10.1158/1078-0432.ccr-09-2446
34. Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P (2011) Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Analytical Cellular Pathology 34(1):61-66. doi: 10.3233/acp-2011-0005
35. V600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology & Metabolism 97(7):2333-2340. doi: 10.1210/jc.2011-3106
36. V600E protein expression in human colon carcinomas. Cancer 119(15):2765-2770. doi: 10.1002/cncr.28133